Search results
Results from the WOW.Com Content Network
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.
A 2016 review found it was not useful in generalized anxiety disorder at 2.5, 5, and 10 mg doses (15 and 20 mg doses were not tested). [32] A 2019 meta-analysis found that vortioxetine did not produce statistically significant results over placebo in the symptoms, quality of life, and remission rates of generalized anxiety disorder, but it was ...
The main indication for SSRIs is major depressive disorder; however, they are frequently prescribed for anxiety disorders, such as social anxiety disorder, generalized anxiety disorder, panic disorder, obsessive–compulsive disorder (OCD), eating disorders, chronic pain, and, in some cases, for posttraumatic stress disorder (PTSD).
Abrupt or rapid discontinuation of mianserin may provoke a withdrawal, the effects of which may include depression, anxiety, panic attacks, [10] decreased appetite or anorexia, insomnia, diarrhea, nausea and vomiting, and flu-like symptoms, such as allergies or pruritus, among others.
The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200 mg per day in divided doses of 50 to 100 mg two to three times per day (e.g., 50 mg–50 mg–100 mg). [ 2 ] [ 7 ] [ 6 ] [ 18 ] [ 1 ] [ 19 ] [ 20 ] It is taken for a few days to a few weeks, but no longer than 12 weeks.
Antidepressant discontinuation syndrome; Other names: Antidepressant withdrawal syndrome [1] Specialty: Psychiatry: Symptoms: Flu-like symptoms, trouble sleeping, anxiety, depression, dissociation, intrusive thoughts, nausea, poor balance, dizziness, sensory changes [2] Usual onset: Within 3 days [2] Duration: Few weeks to months [3] [4] Causes
Social anxiety disorder; Panic disorder; Chronic pain syndromes [20] Vasomotor symptoms of menopause (hot flashes) [21] 1994: The first and most commonly used SNRI. It was introduced by Wyeth in 1994. The reuptake effects of venlafaxine are dose-dependent. At low doses (<150 mg/day), it acts only on serotonergic transmission.
Tofisopam [3] (Emandaxin, Grandaxin, Sériel) is an anxiolytic that is marketed in several European countries. [4] Chemically, it is a 2,3-benzodiazepine. Unlike other anxiolytic benzodiazepines (which are generally 1,4- or 1,5-substituted) however, tofisopam does not have anticonvulsant, sedative, [5] skeletal muscle relaxant, motor skill-impairing or amnestic [6] properties.